Compare · MDLN vs NEPH
MDLN vs NEPH
Side-by-side comparison of Medline Inc. (MDLN) and Nephros Inc. (NEPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and NEPH operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.40B, about 1206.5x NEPH ($36.8M).
- Over the past year, MDLN is down 17.1% and NEPH is down 0.9% - NEPH leads by 16.2 points.
- MDLN has hit the wire 20 times in the past 4 weeks while NEPH has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 0 for NEPH).
- Company
- Medline Inc.
- Nephros Inc.
- Price
- $33.80+0.58%
- $3.42-0.29%
- Market cap
- $44.40B
- $36.8M
- 1M return
- -19.55%
- +9.44%
- 1Y return
- -17.07%
- -0.87%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 20
- 0
- Recent ratings
- 25
- 0
Nephros Inc.
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company operates through three segments: Water Filtration, Pathogen Detection, and Renal Products. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company develops and sells water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. Nephros, Inc. was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)
Latest NEPH
- Nephros Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Nephros Announces Financial Results for Quarter Ended March 31, 2026
- SEC Form 10-Q filed by Nephros Inc.
- Amendment: SEC Form 10-K/A filed by Nephros Inc.
- Nephros Schedules First Quarter 2026 Financial Results Conference Call
- Nephros Expands Strategic Focus in Greater New York Market with Dedicated Regional Leadership
- Nephros Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning Expertise
- Nephros Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 4 filed by Banks Robert R. Jr.
- SEC Form 4 filed by Krandel Judy